SCHEMBL24256672

SCHEMBL24256672

CCCc1nc2oc(C(=O)NCCc3ccc(OC)c(OC)c3)c(N)c2c2c1CCC2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.51
GAA P10253 2/20 0.51
ALDH1A1 P00352 5/20 0.49
MAPT P10636 3/20 0.47
SMN1; SMN2 Q16637 5/20 0.47
NAMPT P43490 1/20 0.47
PARP1 P09874 1/20 0.46
POLB P06746 3/20 0.45
TP53 P04637 1/20 0.45
ALOX15 P16050 1/20 0.45
MEN1 O00255 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
KDM4E B2RXH2 1/20 0.44
MITF O75030 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
HPGD P15428 1/20 0.44
CYP2C19 P33261 1/20 0.44
HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26780510 0.83 MAPT (0.53) KMT2AGAAALDH1A1MAPTSMN1; SMN2
SCHEMBL24256612 0.82 MTOR (0.60) KMT2AGAAALDH1A1MAPTSMN1; SMN2
SCHEMBL24256709 0.81 MTOR (0.61) KMT2AGAAALDH1A1MAPTSMN1; SMN2
SCHEMBL24256707 0.76 MTOR (0.58) KMT2AGAAALDH1A1MAPTSMN1; SMN2
SCHEMBL24256669 0.75 MTOR (0.48) KMT2AGAAALDH1A1MAPTSMN1; SMN2
SCHEMBL26780496 0.73 KDM4E (0.56) KMT2AGAAALDH1A1MAPTPOLB
SCHEMBL24256903 0.73 KDM4E (0.56) KMT2AGAAALDH1A1MAPTPOLB
SCHEMBL24256357 0.73 MTOR (0.53) KMT2AGAAALDH1A1MAPTSMN1; SMN2
SCHEMBL24256901 0.72 KDM4E (0.77) KMT2AGAAALDH1A1MAPTPOLB
SCHEMBL24256858 0.72 MTOR (0.63) KMT2AGAAALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-11-16 US disclosed
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-11-16 US disclosed
WO-2022035806-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP30, USP8 KMT2A 1456/4885GAA 277/4885ALDH1A1 1934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.